跳至主要内容
临床试验/NCT00135967
NCT00135967已完成2 期

Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study

Radboud University Medical Center2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2002年5月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
30
试验地点
2
主要终点
renal function (serum creatinine)

研究概览

简要总结

Patients with idiopathic membranous nephropathy and renal insufficiency are at risk for end-stage renal disease (ESRD). Treatment with cyclophosphamide is currently used as a treatment modality. Mycophenolate mofetil is a new immunosuppressive agent with fewer side effects.

In this pilot study patients with membranous nephropathy and renal failure will be treated with mycophenolate mofetil and prednisone. The outcome will be compared with historical controls treated with a similar regimen containing cyclophosphamide.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Membranous nephropathy
  • Serum creatinine (Screat)> 1,5 mg/dl or ECC < 70 ml/min or increase Screat > 50%
  • Proteinuria > 2 g/day

排除标准

  • Systemic diseases
  • Pregnancy wish
  • Active infection
  • Liver dysfunction
  • Abnormal hematology lab
  • Unstable angina
  • Nonsteroidal anti-inflammatory agents (NSAIDs)

结局指标

主要结局

renal function (serum creatinine)

proteinuria

次要结局

  • side effects
  • relapse rate

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验